Syndax Pharmaceuticals falls as Q3 revenue misses estimates
NegativeFinancial Markets

Syndax Pharmaceuticals has reported disappointing Q3 revenue figures that fell short of analysts' expectations, leading to a decline in its stock price. This news is significant as it raises concerns about the company's financial health and future growth prospects, potentially affecting investor confidence and market perception.
— Curated by the World Pulse Now AI Editorial System









